Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.

Menaka PaiNeill K J AdhikariMarlies OstermannDiane Heels-AnsdellJames D DouketisYoanna SkrobikIsmael QushmaqMaureen MeadeGordon GuyattWilliam GeertsMichael W WalshMark A CrowtherJan O FriedrichLisa BurryRinaldo BellomoNilton Brandão da SilvaRubens Costa FilhoMichael J CoxSuzana Alves SilvaDeborah J Cooknull null

Published in: PloS one (2018)

In critically ill patients with ESRD, or severe renal dysfunction, there was no significant difference in any VTE or major bleeding between UFH and dalteparin. Patients with severe renal dysfunction who received dalteparin had more proximal DVTs than those on UFH; this finding did not hold in patients with ESRD alone.

Keyphrases

venous thromboembolism
oxidative stress
phase iii
atrial fibrillation
direct oral anticoagulants
end stage renal disease
growth factor
phase ii
drug induced
open label